Sionna Therapeutics is trading at $3.60, down 5.26%; no company-specific announcement explaining the October 23 decline was identified.

  • Sionna’s latest listed release was October 8, about previously disclosed trial analyses and conference data.
  • The Dow is down 1.11%, while the S&P 500 and Nasdaq are down less than 0.5%.
  • A broader-market cause for the decline is unclear.